Swedish Orphan Biovitrum (BIOVF) Projected to Release Earnings on Thursday

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) is expected to be releasing its resultson Thursday, July 16th. Analysts expect Swedish Orphan Biovitrum to post earnings of $0.38 per share and revenue of $752.6510 million for the quarter.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.07. The firm had revenue of $755.76 million for the quarter, compared to the consensus estimate of $749.76 million. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%. On average, analysts expect Swedish Orphan Biovitrum to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Swedish Orphan Biovitrum Stock Performance

OTCMKTS BIOVF opened at $48.00 on Thursday. Swedish Orphan Biovitrum has a 52 week low of $27.06 and a 52 week high of $48.00. The company has a 50 day moving average price of $47.48 and a 200 day moving average price of $41.52. The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19. The firm has a market cap of $17.09 billion, a PE ratio of 160.00 and a beta of 0.35.

Analysts Set New Price Targets

Several research firms have issued reports on BIOVF. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Pareto Securities lowered Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Zacks Research raised Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Finally, HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating on the stock. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.